The Depiction of Coronal Structure in White Light Images
Coronary disease
Coronary diseaseCoronary heart disease is the narrowing or blockage of the coronary arteries, usually caused by atherosclerosis. Atherosclerosis (sometimes called “hardening” or “clogging” of the arteries) is the buildup of cholesterol and fatty deposits (called plaques) on the inner walls of the arteries. These plaques can restrict blood flow to the heart muscle by physically clogging the artery or by causing abnormal artery tone and function.Without an adequate blood supply, the heart becomes starved of oxygen and the vital nutrients it needs to work properly. This can cause chest pain called angina. If blood supply to a portion of the heart muscle is cut off entirely, or if the energy demands of the heart become much greater than its blood supply, a heart attack (injury to the heart muscle) may occur.It is most commonly equated with atherosclerotic coronary artery disease, but coronary disease can be due to other causes, such as coronary vasospasm, where the stenosis to be caused by spasm of the blood vessels of the heart it is then usually called Prinzmetal's angina.CausesCoronary artery disease, the most common type of coronary disease, which has no clear etiology, has many risk factors, including smoking, radiotherapy to the chest, chest pains, hypertension, obesity, diabetes, high alcohol consumption, lack of exercise, inability to manage stress, and hyperlipidemia.Also, having a type A behavior pattern, a group of personality characteristics including time urgency and competitiveness, is linked to an increased risk of coronary disease.TreatmentLifestyle changes and reversibilityLifestyle changes have been shown to be effective in reducing (and in the case of diet, reversing) coronary disease:∙ A plant-based diet has been shown by Caldwell Esselstyn and T. Colin Campbell among others to be hugely effective as a treatment of coronary disease, and generalizedatherosclerosis. In numerous peer reviewed studies the progression of heart disease hasbeen shown to halt, and in some cases, the disease process may be reversed. Informationrecommending the reduction of animal based foods and an increase in plant based foodshas been established for over 50 years.∙Weight control∙Smoking cessation∙Avoiding the consumption of trans fats (in partially hydrogenated oils)∙Exercise∙Fish oil consumption to increase omega-3 fatty acid intakeMedications to treat coronary disease∙Cholesterol lowering medications, such as statins, are useful to decrease the amount of "bad" (LDL) cholesterol.∙Nitroglycerin∙ACE inhibitors, which treat hypertension and may lower the risk of recurrent myocardial infarction∙Calcium channel blockers and/or beta-blockers∙AspirinSurgical intervention∙Angioplasty∙Stents (bare-metal or drug-eluting)∙Coronary artery bypass∙Heart transplant。
2021医学考研复试:呼吸内科[SC长难句翻译文]
SCI长难句呼吸内科第一章—社区获得性肺炎Community-acquired pneumonia is still a significant cause of morbidity and mortality and is often misdiagnosed and inappropriately treated.Although it can be caused by a wide variety of micro-organisms, the pneumococcus,atypicals,Staphylococcus aureus and certain Gram-negative rods are the usual pathogens encountered.Antimicrobial therapy should be started as soon as possible particularly in those requiring admission to hospita.社区获得性肺炎仍然具有很高的发病率和死亡率,且经常被误诊和不恰当地治疗。
虽然它可以由多种微生物引起,但涉及的常见病原体有肺炎球菌、非典型球菌、金黄色葡萄球菌和某些革兰氏阴性杆菌。
特别是(对于)那些需要住院的患者,抗菌治疗应尽快开始。
知识点总结:1pneum(o)-前缀,肺2pneumonia n.肺炎3pneumococcus n.肺炎球菌4atypical adj.非典型的5Staphylococcus aureus n.金黄色葡萄球菌6Gram-negative rods n.革兰氏阴性杆菌7pathogen n.病原体8antimicrobial adj.抗菌的Mandell munity-acquired pneumonia:An overview.Postgrad Med.2015 Aug;127(6):607-15.SCI长难句呼吸内科第二章—肺脓肿A lung abscess is an infectious pulmonary disease characterised by the presence of a pus-filled cavity within the lung parenchyma.The content of an abscess often drains into the airways spontaneously,leading to an air-fluid level visible on chest X-rays and CT scans. Primary lung abscesses occur in patients who are prone to aspiration or in otherwise healthy individuals;secondary lung abscesses typically develop in association with a stenosing lung neoplasm or a systemic disease that compromises immune defences,such as AIDS,or after organ transplantation.肺脓肿是一种感染性肺部疾病,其特征是肺实质内有充满脓的空洞。
老年人骨质疏松症合并肌少症治疗的研究进展
随着社会人口老龄化的加剧,各种老年慢性疾病引起了医务工作者和社会各界的重视,其中7.5%的老年性疾病约为骨骼和肌肉类疾病[1]。
骨质疏松症是一种以骨量降低、骨组织微观结构退化和骨脆性增大为特征的,导致机体易发生微创性骨折的全身性骨骼性疾病。
肌肉减少症多发生于老年人,是一种以全身肌量减少、肌力下降和生理功能衰退等为特点的慢性综合征。
骨量在人体30岁时达到巅峰,然后开始下降,绝经后的女性骨量下降尤为快速;肌肉量在25岁时达到峰值, 40岁后每年肌肉质量会以约1%~2%的速度流失,80岁时肌量已流失约30%,其中肌肉力量和强度的下降速度明显大于肌肉质量[2]。
骨质疏松会增加跌倒的风险;而肌量减少和功能下降,会降低力量,导致活动功能受限,也提高了跌倒和骨折的风险[3]。
因此对“肌少-骨质疏松症”及早进行干预可降低跌倒和骨折的风险。
然而目前对“肌少-骨质疏松症”还没有直接有效的治疗方法,运动营养、干细胞治疗以及分子药物治疗等相关研究成为该病治疗的主要方向。
该文就目前老年人骨质DOI:10.16662/ki.1674-0742.2021.09.196老年人骨质疏松症合并肌少症治疗的研究进展陈周韬1,陈光华2,吴新诱2,谭小艳2,黄贵芝21.广东医科大学研究生院,广东湛江524023;2.广东医科大学附属医院骨科,广东湛江524001[摘要]社会人口老龄化导致许多老年慢性病的患病率逐年上升,而骨质疏松症和肌肉减少症正是与增龄明显相关的退行性疾病。
越来越多的研究表明肌肉和骨骼、肌肉减少症和骨质疏松症之间互相影响,它们使老年人的骨脆性增加和虚弱,导致其功能衰退、跌倒、骨折、住院、丧失独立性和死亡的风险升高,并降低了老年人的生活质量。
近年关于两者发病机制的研究取得了重大进展,但针对“肌少-骨质疏松症”共同靶点的治疗方法和药物比较缺乏。
但有文献表明有效的运动营养、干细胞治疗以及一些分子药物可以同时对肌肉和骨骼产生积极的影响,这些治疗方法都能使老年人发生跌倒及骨折的风险大大降低。
冠脉介入术后再发血栓的机制及相关防治
冠脉介入术后再发血栓的机制及相关防治王鸿叶1雷超海“1.牡丹江医学院附属红旗医院心内科,黑龙江牡丹江157000;2.牡丹江医学院附属红旗医院外科,黑龙江牡丹江157000;[摘要]经皮冠状动脉介入治疗(PCI)的发展为急性冠脉综合征(ACS)患者带来前所未有的曙光,但支架内血栓的形成仍是医疗技术发展所要攻克的难题。
支架内血栓形成是一种罕见的冠状动脉介入治疗的并发症,并与随后的不良事件有关。
从早期的单纯球囊扩张到药物涂层支架技术的不断改进,支架内血栓的发生率显著降低。
同时,针对患者既往病史及个体化风险评估、抗凝及抗血小板药物的应用、对冠脉内早期血栓识别技术的发展、冠脉支架的选择及血栓抽吸术的应用都是减少支架内血栓发生的重要环节。
现从冠脉介入术后支架内血栓形成的诱因、机制及相关防治进行概述。
[关键词]经皮冠状动脉介入治疗;支架内血栓形成;抗凝药物;抗血小板药物;高凝状态[中图分类号]R541[文献标识码]A[文章编号]1674-4721(2021)3(c)-0047-04Mechanism and related prevention and treatment of recurrence of thrombus after coronary interventionWANG Hong-ye1LEI Chao-haP银1.Department of Cardiology,Hongqi Hospital Affiliated to Mudanjiang Medical University,Heilongjiang Province,Mu-danjiang157000,China;2.Department of Surgery,Hongqi Hospital Affiliated to Mudanjiang Medical University, Heilongjiang Province,Mudanjiang157000,China[Abstract]The development of percutaneous coronary intervention(PCI)has brought unprecedented wish to patients with acute coronary syndrome(ACS),but the stent thrombosis is still a difficult problem to be overcome in the development of medical technology.Stent thrombosis is a rare complication of coronary intervention and is related to subsequent adverse events.From the early simple balloon expansion to the continuous improvement of drug-coated stent technology,the incidence of stent thrombosis has been markedly reduced.Meanwhile,assessment on patient's past medical history and individualized risk,the application of anticoagulant and antiplatelet drugs,the development of early coronary thrombus recognition technology,the selection of coronary stents,and the application of thrombus aspiration serve as important parts for stent thrombosis reduction.This article summarized the causes,mechanisms and related prevention and treatment of stent thrombosis after coronary intervention.[Key words]Percutaneous coronary intervention;Stent thrombosis;Anticoagulant drugs;Antiplatelet drugs;Hypercoag-ulable state根据支架内血栓发生的时间2007年美国学术研究联合会(ARC)的分层中定义急性期<24h、亚急性期<24h~30d、晚期<30d~1年、极晚期>1年[1]。
Inversion of coronal Zeeman and Hanle Observations to reconstruct the coronal magnetic fiel
Inபைடு நூலகம்ersion
1. Introduction
The coronal magnetic field is the main driving force for most plasma processes in the inner corona. To understand the physics of the corona a detailed knowledge of the state of the coronal field is therefore essential. Unlike the photosphere, however, the low density and high temperature of the coronal plasma make direct field measurements in the corona to be rather difficult. Conventionally, the magnetic field of the corona is therefore estimated by means of extrapolations from its photospheric boundary values. Until now, potential field apSend offprint requests to: B. Inhester
The above crude picture, however, also a neglects the fact that the coronal observations are line-of-sight integrals through an optically thin medium and do not represent directly its local properties. The goal of our study is to obtain a more sophisticated interpretation of the observations also in this respect. In particular, we want to investigate the whether these observations suffice to determine a global model of the coronal magnetic field. Due to a lack of space we can here only briefly discuss the approach we have adopted (chapter 2) and present initial results of some of our test calculations (chapter 3). Necessary future work work is outlined in the final section (chapter 4). More details can be found in Kramar (2005) and Kramar et al. (2006).
化学英语课件
( ):
[ ]: { }:
rounds brackets, parenthese
square brackets braces
a>>b: a is much greater than b ab: a is greater than or equal to b
ab: a varies directly as b
P-block Element
IIIA B: boron Al: Aluminium Ga: Gallium In: Indium Tl: Thallium
IVA C: Si: Ge: Sn: Pb:
VA
Carbon Silicon Germanium Tin Lead
N: P: As: Sb: Bi:
3. fundamental constants
Symbol Quantity
e
F g
elementary charge
Faraday‘s constant gravitational acceleration
h
k NA R Vm
Planck‘s constant
Boltzmann‘s constant Avogadro‘s number molar gas constant gas molar volume
Nitrogen Phosphorus Arsenic Antimony Bismuth
P-block Element
VIA O: S: Se: Te: Po:
VIIA Oxygen Sulfur Selenium Tellurium Polonium
F: Fluorine Cl: Chlorine Br: Bromine I: Iodine At: Astatine
青蒿素——一种从中药中发现的神奇药物
ResearchTraditional Chinese Medicine—ReviewArtemisinin,the Magic Drug Discovered from Traditional ChineseMedicineJigang Wang a ,b ,c ,d ,#,Chengchao Xu c ,#,Yin Kwan Wong d ,#,Yujie Li a ,b ,Fulong Liao a ,b ,Tingliang Jiang a ,b ,Youyou Tu a ,b ,⇑aArtemisinin Research Center,China Academy of Chinese Medical Sciences,Beijing 100700,ChinabInstitute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China cDepartment of Pharmacology,Yong Loo Lin School of Medicine,National University of Singapore,Singapore 117600,Singapore dDepartment of Physiology,Yong Loo Lin School of Medicine,National University of Singapore,Singapore 117597,Singaporea r t i c l e i n f o Article history:Received 8June 2018Revised 1August 2018Accepted 12November 2018Available online 18December 2018Keywords:ArtemisininMechanism of action Malaria Anti-cancera b s t r a c tArtemisinin and its derivatives represent the most important and influential class of drugs in the fight against malaria. Since the discovery of artemisinin in the early 1970s, the global community has made great strides in characterizing and understanding this remarkable phytochemical and its unique chemical and pharmacological properties. Today, even as artemisinin continues to serve as the foundation for antimalarial therapy, numerous challenges have surfaced in the continued application and development of this family of drugs. These challenges include the emergence of delayed treatment responses to artemisinins in malaria and efforts to apply artemisinins for non-malarial indications. H ere, we provide an overview of the story of artemisinin in terms of its past, present, and future. In particular, we comment on the current understanding of the mechanism of action (MOA) of artemisinins, and emphasize the impor-tance of relating mechanistic studies to therapeutic outcomes, both in malarial and non-malarial contexts.Ó 2019 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license1.IntroductionMalaria has been a debilitating disease with global influence since ancient times and continues to be one of the most wide-spread and damaging infectious diseases today [1].With the cause of disease having long been misattributed to ‘‘bad air,”the trans-missible and parasitic nature of malaria remained unknown until the works of Charles Louis Alphonse Laveran and Ronald Ross in the late 1800s.Their findings established that protozoa belonging to the genus Plasmodium caused malaria,and that Anopheles mos-quitoes were the primary vectors of malarial infections.These observations made Laveran and Ross two of the earliest recipients of the Nobel Prize in Physiology or Medicine [2].In the decades following their discoveries,ground-breaking progress has been made in the battle against the disease.The cru-sade launched by the Chinese government in the late 1960s to search for cures for malaria ultimately culminated in the discovery of artemisinin.Artemisinin (and its various derivatives,which we will refer to collectively as ‘‘artemisinin”unless otherwise speci-fied)is a sesquiterpene lactone compound (Fig.1)with a unique chemical structure derived from the sweet wormwood plant,Artemisia annua L.(Fig.2).Since its discovery,it has become the most important and effective antimalarial drug [3].In many ways,artemisinin is a truly fascinating drug.From the tumultuous process of its discovery,which was deeply tied to tra-ditional Chinese medicine (TCM),to its remarkable potency and impact as an antimalarial drug,it is not surprising that artemisinin has captured a great deal of attention since its introduction to the world stage [1].Over 40years after its discovery,artemisinin remains our bulwark against malaria and is the foundation of all major antimalarial therapies [4].Years of research spanning a range of disciplines have gone into the exploration and elucidation of the mechanisms of artemisinin in its antimalarial role [5].Beyond that,efforts have been made to repurpose artemisinin for non-malarial applications,thereby raising considerable anticipa-tion over the future development of this drug [6].With that in mind,we feel that it is a good time to broadly review the timeline of this influential drug,spanning its past,present,and future.Beginning with a look back at the story of the discovery and development of artemisinin,we then review⇑Corresponding author.E-mail address:yytu@ (Y.Tu).#These authors contributed equally.and discuss the contemporary understanding of the mechanism of action (MOA)of artemisinin in malaria.We conclude by looking ahead at current efforts to repurpose artemisinin for possible roles outside of malaria.We believe that this article will provide a well-rounded background of artemisinin,along with relevant insights into the salient topics surrounding this remarkable drug.2.The journey of discoveryWe begin with a brief tracing of the remarkable journey that led to the discovery and development of artemisinin.Records of malaria in TCM date back thousands of years,and the same is true for the usage of Artemisia (Qinghao)plants as medicinal herbs.First mentioned as a specific remedy for malarial symptoms in Ge Hong’s Zhouhou Beiji Fang (Handbook of Prescriptions for Emergency )dating back to the Eastern Jin Dynasty (317–420AD),the application of Qinghao and other techniques for malarial relief was subsequently noted in a series of historical Chinese medical writings that included the influential Bencao Gangmu (Compendium of Materia Medica )by Li Shizhen (Ming Dynasty,1368–1644AD).This wealth of ancient knowledge would later prove to be instrumental in the discovery and development of artemisinin.In the years following World War II,the development and deployment of the potent insecticide dichloro-diphenyl-trichloro-ethane (DDT)and new antimalarial drugs such as chloroquine (CQ)resulted in great progress in combating malaria.However,the World Health Organization (WHO)’s campaign in the 1950s to combat and eradicate malaria around the world was eventually met with challenges related to resistance.The emergence of DDT-resistant vectors and drug-resistant parasites led to a rebound of the disease,especially in regions such as Southeast Asia and sub-Saharan Africa [7].This setback prompted an urgent need for novel antimalarial drugs.Significant efforts had been made by the United States due to the Vietnam War and the prevalence of drug-resistant malaria in that region.The Chinese government also initiated efforts in malarial research around this time.In particular,a national project called Project 523(named after its date of inau-guration,23May 1967)was set up to consolidate malarial research on a national level [8].In 1969,Professor Youyou Tu was selected to lead a research group within the project that focused on screening TCM for novel antimalarial drugs.This work took place at the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences.Drawing from a massive repository of TCM knowledge that included ancient literature,folklore,and oral interviews with prac-titioners,Tu and colleagues worked from a list of over 2000herbal remedies,of which some 640were deemed to be possible ‘‘hits.”From this selection,over 380extracts from approximately 200herbs (including Qinghao/Artemisia extracts)were eventually collected and tested,mostly giving unsatisfactory results [1,9].The Qinghao extract nevertheless drew particular interest starting around 1971,as it produced promising but inconsistent results [1].This finding prompted a revisitation of the literature,and led to perhaps the most important breakthrough in the discovery process.Returning to the earliest record of the use of Qinghao to treat malarial symptoms,which was in Ge Hong’s Zhouhou Beiji Fang (Handbook of Prescriptions for Emergency ),Tu noted that the instructions for the Qinghao prescription involved consuming the strained ‘‘juice”of the Qinghao plant immersed in water.It was notable that the instruction made no mention of heating the medicine—something that was otherwise common for prescrip-tions in TCM.Drawing from the literature and her own knowledge of TCM,Tu arrived at the idea to modify the extraction process to use low-temperature conditions.The extracts produced from this new procedure were further purified by separation of the acidic and neutral phases in order to retain active components while reducing the toxicity of the original extract.The resultant substance displayed a striking 100%effectiveness against rodent malaria in experiments carried out around October 1971.This remarkable result was then fully reproduced in monkey malaria experiments carried out in late December of the same year,thus establishing the efficacy of the Qinghao extract beyond doubt [1].Fig.1.Artemisinin and its clinically usedderivatives.Fig.2.Artemisia annua L.in the field.J.Wang et al./Engineering 5(2019)32–3933The breakthrough had been made,but the journey of drug development was by no means complete.Conditions in China at that time made it difficult to perform clinical trials of new drug candidates to ascertain their safety for humans.In an attempt to accelerate the process due to the seasonal and time-sensitive nat-ure of malarial research,Tu and colleagues decided to volunteer themselves as thefirst human subjects for toxicity and dose-finding tests[8].This act established the safety profile of the Qinghao extract and enabled clinical trials to be carried out imme-diately,in the latter half of1972.The trials(which were carried out in Hainan Province and at the302Hospital PLA(now incorporated into the Fifth Medical Center of the Chinese PLA General Hospital) in Beijing)proved successful,and paved the way for Qinghao research to be pushed to the national level.A subsequent concerted effort on the part of the Chinese scientific community at large drove further research and development of Qinghao forward.The active component of the Qinghao extract,artemisinin(also known as Qinghaosu)itself,was isolated in November1972by Tu’s team at the Institute of Chinese Materia Medica.The team would later go on to develop dihydroartemisinin(DHA),which remains one of the most pharmacologically relevant derivatives today.In collabora-tion with other institutes across China,further groundwork in drug development,including the determination of the stereo-structure of artemisinin and further derivatization of artemisinin,was carried out in the following decade[10,11].These efforts,among others,culminated in the fourth meeting of the Scientific Working Group on the Chemotherapy of Malaria held in Beijing in1981, where thefindings were presented by Tu for thefirst time.The results were published in1982as a series of papers under the name‘‘China Cooperative Research Group on Qinghaosu and Its Derivatives as Antimalarials”[12,13];thus the gift from Chinese medicine was delivered to the rest of the world.In the subsequent years of the1980s,artemisinin and its deriva-tives were successfully employed in China to treat thousands of malaria patients[1].As the problem of drug-resistant malaria con-tinued to worsen elsewhere,it was not long before the commence-ment of clinical studies with artemisinin in other endemic regions in Asia[14–19].Consistent and encouraging results led to the expansion of such studies,particularly toward Africa[19–24]. The evidence was clear that artemisinin-based therapy,especially in combination with a slower-acting antimalarial such as meflo-quine or piperaquine,led to significant improvements in parasite clearance and a rapid diminishing of symptoms for both uncompli-cated and severe Plasmodium falciparum malaria infection.At the same time,its tolerability was shown to be excellent,as reports of toxicity and safety concerns remained minimal[25].Across more than a decade’s worth of independent randomized clinical studies and meta-analyses,the outstanding efficacy and safety of artemisinin-based therapy became increasingly clear.Finally,in 2006,the WHO announced an alteration of its strategy to fully employ artemisinin combination therapies(ACTs)as thefirst-line treatment against malaria[26].ACTs remain the most effective and recommended antimalarial therapies today[4].3.The search for a mechanism of actionIt has been more than a decade since the implementation of ACTs as the officialfirst-line treatment for malaria and over three decades since the discovery of artemisinin.In this time,the clinical and pharmacological characteristics of artemisinin therapy have been extensively scrutinized and reported[27–30].Although the specifics of various derivatives can differ,artemisinin drugs are characterized by rapid action and potency,low toxicity,and a short half-life,which makes combination therapy with longer-acting antimalarial drugs ideal and recommended[30].Apart from its pharmacological properties,elucidating the MOA of a drug is important for optimizing treatment regimens.Dosages,drug com-binations,and even considerations of drug resistance are closely related to the molecular basis of a drug’s activity.It is thus some-what surprising that despite decades of widespread application, our understanding of the MOA of artemisinin remains fairly incom-plete.Here,we provide a brief overview of the prevailing under-standing as well as more recent developments in mechanistic studies of artemisinin[31,32].In general,the outstanding thera-peutic properties of artemisinin can be thought of as a result of two major processes:its unique mechanism of activation,and its downstream activity and drug targets.These mechanisms combine to yield a highly potent,yet highly specific,drug.3.1.Drug activationArtemisinin and its derivatives are sesquiterpene lactones that bear the1,2,4-trioxane moiety as the pharmacophore[33].In particular,the endoperoxide bridge within this group is well understood to be essential for the pharmacological activity of artemisinin[13,34,35].Artemisinins are prodrugs in two senses:first,many derivatives are rapidly converted to DHA in vivo,and second,their MOA depends on activation by cleavage of the endoperoxide bridge.The mechanism of this cleavage remains an issue in active research[36].Malarial parasites are characterized by extensive hemoglobin uptake and digestion during the erythrocytic stage of their life cycle[37,38].This releases copious amounts of free redox-active heme and free ferrous iron(Fe2+), which are thought to underlie the parasite specificity of artemisi-nin.Indeed,hemoglobin digestion has been strongly linked with artemisinin susceptibility in parasites[38,39].Multiple models have been proposed with regard to the mechanism of endoperoxide cleavage by either free redox-active heme or free ferrous iron, and the downstream molecular events that follow cleavage [36,40–48].These proposals differ in terms of the nature of the cleavage and the identity of the reactive intermediates produced by drug activation.In general terms,however,they explain the parasite-specific drug activation through which reactive species are produced,leading to cellular damage and parasite killing. Recent evidence suggests that free redox-active heme may play a predominant role in drug activation[49,50].A2008study provided in vitro data that indicated that ferrous heme may be a stronger activator of artemisinin than other iron-containing species,includ-ing hemin,free ferrous iron,and undigested hemoglobin[49]. Similar observations were made in live parasites,in which artemisinin activation was blocked by inhibiting hemoglobin digestion but not by the chelation of free ferrous iron[47].Thus, the process of hemoglobin digestion in infected erythrocytes, which is required for parasite growth,is the key to the specificity of artemisinin activation[38].Interestingly,in studies using yeast cells as a proxy for malaria parasites[51,52],it was found that mitochondria were directly involved in both the activation and action of artemisinin,thus fur-ther linking artemisinin action to reactive oxidative species(ROS) production and oxidative damage.It is also plausible that multiple redundant activation pathways may exist in different environ-ments or localities,where the conditions and magnitude of activa-tion can differ[53].Looking ahead,it will be crucial to consider the pivotal role of drug activation in the activity of artemisinin and to further elucidate its mechanisms under different conditions.3.2.Downstream mechanismThe crucial step in elucidating a drug’s MOA is to identify its cel-lular targets.In the conventional understanding of drug design and mechanisms,a drug modifies one or more specific cellular targets, such as proteins,in order to effect downstream changes.However,34J.Wang et al./Engineering5(2019)32–39the exceedingly fast-acting and potent nature of artemisinin activ-ity,taken together with its ability to alkylate targets,may be due to quite a different mechanism.First of all,heme releases from hemoglobin digestion functions that lie beyond drug activation,as previously outlined.Excess heme is converted in infected erythrocytes to hematin,which is toxic to the parasite via oxidative damage and direct lysis of cell membranes [54].Malarial parasites have therefore evolved a detoxifying mech-anism that converts hematin to the nontoxic and inert crystallized hemozoin via a biocrystallization process[55].Activated artemisi-nin has been reported to prevent the formation of hemozoin by alkylating heme;therefore,it functions in a similar capacity to other antimalarial drugs that act on hemozoin formation,such as CQ [45,56–58].Thus,free heme from hemoglobin digestion serves as both the activator and the target of artemisinin[45].Given that activated artemisinin is thought to generate ROS,it is unsurprising that artemisinin has also been reported to directly alkylate protein targets[59,60].The translationally controlled tumor protein(TCTP)and the Plasmodium sarco/endoplasmic retic-ulum Ca2+-ATPase PfATP6were among thefirst targets of interest that were identified as interacting partners of artemisinin [61–63].Consideration of the role of single targets in the activity of artemisinin has now evolved into MOAs that may depend on multiple targets,as later studies have shown[64–67].Using unbiased proteomics methods,it has been observed that artemisinin targeting may be promiscuous rather than monotarget-specific.In thefirst study that systematically reported artemisinin binding targets,over100proteins were identified in live parasite strains [47].An independent study carried out by Ismail et al.[68]led to consistentfindings.These results support a promiscuous mecha-nism of artemisinin targeting in which activated artemisinin alkylates and damages many cellular proteins,thereby disrupting multiple key biological functions and resulting in toxicity and lethality in parasites[47,48,50].Interestingly,PfATP6and other key transporters such as PfCRT and Pfmdr1are consistently labeled in these types of experiments.Thesefindings are consistent with PfATP6being an important target for artemisinins[47,68].As an independent line of evidence,the mapped binding sites of artemi-sinin to TCTP further support a heme-activated promiscuous mechanism in which modification sites are proximity-based and essentially random[50].Our current knowledge of artemisinin paints a picture of a drug with a unique and elegant mechanism.Artemisinin and its deriva-tives are prodrugs that absolutely require endoperoxide group cleavage for drug activation and subsequent anti-parasite activity. Artemisinin activation is dependent on a heme-rich environment, which is specific to infected erythrocytes as well as being an unavoidable outcome of parasite metabolism.The heme-rich envi-ronment itself is then exploited by the activated drug to achieve efficient parasite killing.This mechanism essentially links infection and parasite growth to drug activation,thus ensuring both the out-standing specificity and the tolerability of artemisinin therapy.At the same time,activated artemisinin indiscriminately damages proximal proteins and cellular structures.Rather than targeting a single protein or cellular function,like the majority of conventional drugs(including most antimalarials),artemisinin acts like a less-discriminative‘‘bomb”that detonates upon activation to cause widespread damage.The specificity of artemisinin may therefore be seen to be based on its activation rather than on its targets. These unique properties of artemisinin make it almost the ideal weapon against malaria,especially in combination with other drugs that act via distinct mechanisms and complement the pharmacological profile of artemisinin.An obvious advantage of a promiscuously targeting drug is also worth noting here:The devel-opment of drug resistance is much more difficult when mutation in one or a few specific targets is not sufficient to seriously impact drug activity.This advantage could well explain why artemisinin has remained generally efficacious despite its ubiquitous use over decades.Nevertheless,recent trends have signaled the incidence and rise of malaria that is being cleared more slowly by ACTs,especially in the Asian endemic regions[69].This topic has been comprehen-sively covered from various angles by recent reviews and commen-taries[69–75].Regardless of the controversies about the exact definition of‘‘artemisinin resistance”in thefield,the threat is undoubtedly real,given the place that artemisinin occupies in the control of malaria[76,77].To resolve this burning issue,two major challenges must be overcome:①A full understanding of the MOA of artemisinin must be achieved;and②the genetic and physiological features of the newly emerged artemisinin-resistant strains must be defined.Even though the MOA of artemisinin has been largely demystified in the past few years, the molecular characterization of artemisinin-resistant malaria is far from clear.Continued efforts are required to achieve a complete picture of how artemisinin resistance relates to its mode of action. Based on this new knowledge,new therapeutic strategies can then be developed and tested.4.Repurposing artemisininArtemisinin therapy is characterized by its outstanding tolera-bility and relative affordability.This combination of proven safety and accessibility make artemisinin a drug of exceptional interest for repurposing studies.Indeed,interest in non-malarial applications of artemisinin has increased steadily over time since artemisinin wasfirst made known to the world[78].While malaria remains the only disease for which artemisinin is an approved treatment,the potential applications of artemisinin in anti-cancer,anti-inflammatory,anti-parasitic(outside of malaria)and anti-viral roles,among others,have been explored in earnest over the years[78–82].Here,we briefly comment on some promising research in artemisinin repurposing,especially in thefield of cancer treatment,as a window into future drug development.The efficacy of artemisinin in cancer cultures wasfirst reported in1993,and has since been expanded on and extensively charac-terized[83–85].It is now well-reported that artemisinin and its derivatives display selective cytotoxicity against a range of cancer types in both in vitro and in vivo studies[86].Forays into clinical testing have been generally promising,if limited in number and scale[87–89].More than two decades of research on the basis of artemisinin action in cancer has uncovered a plethora of impli-cated targets and mechanisms.Artemisinin has been reported to induce mitochondrial apoptosis and other forms of cell death such as necroptosis,inhibit cancer angiogenesis and metastasis,and arrest the cancer cell cycle[90–97].These outcomes are reportedly mediated by a combination of oxidative damage,DNA damage, alteration of gene expression,and interactions with a wide array of signaling pathways including mammalian target of rapamycin (mTOR),NF-j B,mitogen-activated protein(MAP)kinases,and Wnt/b-catenin,among many others[82,98–102].These pathways and mechanisms have been extensively reviewed in recent publications[79–82].While pathway validation is an important aspect of mechanistic study,it is also necessary to consider the big picture in terms of unifying drug activation and downstream activity in a manner similar to what was done in malaria studies.As is the case with malarial parasites,the activation mechanism of artemisinin in can-cer cells is likely to be heavily linked to its specificity of action. Thus,the role of free ferrous iron versus free redox-active heme is once again being put under scrutiny,especially considering that iron is intimately linked to artemisinin-induced cytotoxicity in cancer[103,104].Recent studies have once again shed light onJ.Wang et al./Engineering5(2019)32–3935the role of heme in artemisinin activation in cancer cells,thereby drawing parallels with the case in malaria.In particular,a range of methodologies have been used to demonstrate that modulation of heme synthesis and availability clearly correlates with cytotox-icity[105–108].It is also important to note that cancer cells have been reported to possess enhanced levels of heme metabolism and synthesis,and that this could underpin the cancer specificity of artemisinin in a similar manner to the case in malaria[109–111].Specific targeting of artemisinin to mitochondria(the site of mammalian cell heme synthesis)or enhancement of heme levels by treatment with the heme precursor aminolevulinic acid(ALA) both improved anti-cancer activity[112–114].A heme-centric mechanism of activation and an iron-dependent mechanism of downstream cytotoxicity could possibly be a point of reconciliation between the roles of those two species in the anti-cancer activity of artemisinin[115].Further work to fully understand the basis of artemisinin specificity in cancer will be critical for future therapeu-tic applications.At the same time,it is necessary to consider the appropriate direction when moving forward in terms of validating artemisinin MOAs in cancer.Consider the case in malaria,where artemisinin is proposed to indiscriminately attack adjacent targets upon activa-tion.If artemisinin is activated in a similar manner in cancer cells, it is plausible that the same promiscuous multi-target mechanism would take place.This would explain the remarkable range of cel-lular effects and implicated pathways that have already been reported,as multiple targets and functional pathways are likely to be simultaneously affected by such a mechanism.Indeed,recent unbiased studies of artemisinin cancer targets using proteomics approaches have revealed a similar multi-target MOA by artemisi-nin in cancer cells[48,113,114].The mechanism of cytotoxicity itself is also a matter of great interest,especially with regard to non-apoptotic forms of cell death.Recent work has closely linked artemisinin-induced cytotoxicity to oxidative damage and lysoso-mal function,with a focus on the role of iron in contributing to the iron-dependent form of cell death known as ferroptosis [116–118].In particular,lysosome-mediated degradation of fer-ritin under autophagy conditions(termed ferritinophagy)releases free ferrous iron,which in turn contributes to both ferroptosis and iron-mediated generation of ROS[93,119].Autophagy itself is a cellular process that is reportedly activated by artemisinin,but has ambiguous effects on cancer cell survival and the cytotoxicity of artemisinin[115,119].It is clear that the relationship between autophagy,lysosomal activity,free ferrous iron,and iron-dependent ferroptotic cell death following artemisinin exposure represents a major area of uncertainty in the anti-cancer mecha-nism of artemisinin.However,efforts in unveiling novel,cancer-specific targets and mechanisms are steadily ongoing and continue to contribute to a grand view of artemisinin as an anti-cancer drug. Artemisinin-mediated effects on cancer stem cells,immunomodu-lation,cancer metastasis,cancer metabolism including the regula-tion of glycolysis,and a plethora of signaling pathways including signal transducer and activator of transcription3(STAT3),NF-j B, mTOR,and CREBP signaling are among recent reports,and indicate novel directions for further validation[115,120,121].In particular, the potential ability of artemisinin to serve as an immunomodula-tor in cancer by regulating regulatory T cell(Treg)activity and the production of pro-cancer-survival immunosuppressive cytokines such as prostaglandin E2(PGE2)is noteworthy,given the complex role of immunomodulatory drugs in cancer therapy[122–125]. Finally,efforts to improve the formulation and delivery of artemisinin-based drugs have shown promise in delivering enhanced efficacy and reduced susceptibility to drug resistance. These results include novel synthetic dimers,trimers,and drug conjugates(especially transferrin-conjugated systems),in addition to combination therapies;they represent an exciting ongoing area of research that has been reviewed comprehensively in recent publications[126–135].In addition to the possible applications of artemisinin in cancer treatment,active research is taking place on its potential roles in addressing a range of other diseases.In particular,anti-inflammatory effects against autoimmune diseases and allergic asthma,among other conditions,have been reported in a range of disease models[78].Some of these results correlate with observa-tions of immunosuppression in patients undergoing artemisinin therapy for malaria[136].Strong anti-viral effects of artemisinin have also been reported in herpes and in hepatitis B and C viruses, and other parasitic diseases including schistosomiasis have also been shown to respond to artemisinin treatment[137–141].Recent findings have even identified a remarkable—if controversial—role of artemisinin in diabetes through inducing transdifferentiation of pancreatic a cells to generate b cells[142,143].The MOA for these alternative applications is frequently discussed in terms of the canonical model of ROS generation and oxidative damage induction upon endoperoxide cleavage;however,non-canonical(including endoperoxide-independent)mechanisms have also been proposed, especially in the case of immunomodulation[78,144].It will be essential to pursue a clear view of how drug mechanisms and func-tions may differ under varying applications and conditions,while considering the importance of the conditions of drug activation.It is also worth noting that repurposing research might be best carried out in patients and regions that are not burdened with or at risk of malaria,in order to avoid possible interference or complications. Every care must be taken to ensure that the full potential of artemisinin can be realized without compromising its current applications.5.ConclusionThe artemisinins are a class of remarkable drugs that have rede-fined the landscape of antimalarial therapy.A combination of out-standing potency,safety,and accessibility has put artemisinin at the forefront of the ongoing battle against the malaria scourge, where it has already impacted millions of lives.Since its discovery, a concerted effort by the global community has assembled a pic-ture of a drug with a unique set of properties that makes it almost the ideal antimalarial drug.Active research in otherfields has also revealed a broad spectrum of promising applications for artemisi-nin outside of malaria.We believe that it is only logical to seek to maximize the utility of this drug in a range of capacities.In the context of malaria,doing so means to continue to clarify the mech-anisms of activation and action of artemisinin,while working to further improve its pharmacological properties both alone and in combination[145].Combined with afirm grasp of the principles of artemisinin activity,this could be the key to clearing the uncer-tainties of artemisinin resistance.Such efforts would ensure that the drug can continue to perform in a similar or even greater capacity within the role that it has served for so long.Looking ahead,repurposing studies driven by a robust understanding of differential MOAs in different diseases and systems will also be instrumental in defining the future of artemisinin.Ultimately,it is our sincere hope that this gift from Chinese medicine can con-tinue to serve the pursuit of health for people all around the world, for many years to come.AcknowledgementsThis work was supported,in whole or in part,by the projects of the National Natural Science Foundation of China(81641002and 81473548);Major National Science and Technology Program of China for Innovative Drug(2017ZX09101002-001-001-05and36J.Wang et al./Engineering5(2019)32–39。
caudate and putamen structures的英文
Abstract:The caudate nucleus and putamen, collectively known as the dorsal striatum, are integral components of the basal ganglia, playing crucial roles in motor control, reward processing, learning, and cognitive function. This comprehensive analysis delves into their anatomical features, neurochemical organization, functional connectivity, involvement in various neurological and psychiatric disorders, and their significance in clinical practice. By examining these structures from multiple angles, this article aims to provide a thorough understanding of their complex interplay and contributions to human behavior.1. IntroductionThe basal ganglia, nestled deep within the cerebral hemispheres, constitute a network of interconnected subcortical nuclei that regulate movement, motivation, and cognitive processes. Among these, the caudate nucleus and putamen stand out as central players, forming the dorsal striatum, a primary input station for cortical information and a critical gateway in the cortico-basal ganglia-thalamo-cortical loop. This loop is fundamental to the modulation of voluntary movements, habit formation, and the integration of sensory, emotional, and cognitive signals. This article explores the intricate anatomy, neurochemistry, functional connectivity, pathophysiological involvement, and clinical implications of the caudate and putamen.2. Anatomical Features and Neurochemical Organization**Caudate Nucleus**: The caudate nucleus, named for its resemblance to a tail (Latin: cauda), is a C-shaped structure extending along the lateral wall of the lateral ventricle. It can be divided into three segments: the head, body, and tail, each with distinct connections to different brain regions. The caudate receives dense projections from the prefrontal cortex, particularly the dorsolateral prefrontal cortex and anterior cingulate gyrus, reflecting its involvement in higher-order cognitive functions.Neurochemically, the caudate is primarily composed of GABAergic medium spiny neurons (MSNs), which constitute over 90% of its neuronal population. These MSNsexpress either dopamine D1 receptors (D1R) or D2 receptors (D2R), giving rise to two parallel pathways: the direct (D1R-expressing) and indirect (D2R-expressing) pathways. The direct pathway facilitates movement by disinhibiting the thalamus, while the indirect pathway inhibits movement through increased inhibition of the thalamus via the globus pallidus externa (GPe) and substantia nigra pars reticulata (SNr).**Putamen**: Located posterior to the caudate and separated from it by the internal capsule, the putamen forms the bulk of the dorsal striatum. It is involved primarily in motor control and receives inputs from the primary motor cortex, premotor cortex, and somatosensory cortex. The putamen also shares similar neurochemical organization with the caudate, being predominantly composed of GABAergic MSNs expressing D1Rs or D2Rs, which give rise to the direct and indirect pathways.3. Functional Connectivity and Roles in Behavior**Motor Control**: Both the caudate and putamen play critical roles in the planning, initiation, and execution of voluntary movements. They integrate sensorimotor information from the cortex and facilitate the selection and execution of appropriate motor responses. The direct and indirect pathways dynamically balance each other, ensuring smooth and coordinated movements. Disruptions in this balance underlie motor symptoms observed in disorders such as Parkinson's disease (PD) and Huntington's disease (HD).**Reward Processing and Learning**: The caudate and putamen are integral to reinforcement learning and the processing of rewards and punishments. They receive dopaminergic projections from the ventral tegmental area (VTA) and substantia nigra pars compacta (SNc), which convey reward prediction error signals that drive learning and adaptation of behavior. The striatal reward system is involved in addiction, where substance-related cues trigger dopamine release, reinforcing drug-seeking behavior.**Cognitive Functions**: The caudate, particularly its anterior portion, is involved in executive functions such as working memory, decision-making, andcognitive flexibility. Its connectivity with the prefrontal cortex suggests a role in integrating cognitive and emotional information for goal-directed behavior. The putamen, though primarily associated with motor functions, also contributes to non-motor cognitive processes like response inhibition and attention.4. Pathophysiological Involvement and Associated Disorders**Movement Disorders**: The caudate and putamen are prominently affected in several movement disorders. In PD, the degeneration of dopaminergic neurons in the SNc leads to reduced dopamine levels in the striatum, causing motor symptoms like bradykinesia, rigidity, and tremors. HD is characterized by the progressive loss of GABAergic MSNs, leading to choreiform movements, cognitive decline, and psychiatric disturbances. In dystonia, abnormal activity in the striatum contributes to involuntary muscle contractions and postures.**Psychiatric Disorders**: The striatum's involvement in reward processing and executive functions renders it susceptible to dysregulation in psychiatric conditions. For instance, in obsessive-compulsive disorder (OCD), hyperactivity in the striatum may underlie repetitive behaviors and intrusive thoughts. In addiction, altered striatal dopamine signaling fosters compulsive drug seeking. In depression and anxiety, dysfunctional cortico-striatal circuits may contribute to anhedonia and maladaptive stress responses.5. Clinical Implications and Therapeutic TargetsUnderstanding the caudate and putamen's functions and pathophysiological roles has significant clinical implications. Neuromodulatory techniques like deep brain stimulation (DBS) target specific striatal regions to alleviate motor symptoms in PD and dystonia. In psychiatric disorders, pharmacological interventions often aim to modulate striatal neurotransmitter systems. For example, dopamine agonists are used in PD, while serotonin reuptake inhibitors are employed in OCD and depression.Moreover, advanced imaging techniques like functional magnetic resonance imaging (fMRI) and positron emission tomography (PET) allow for the in vivoassessment of striatal function and neurochemistry, facilitating diagnosis and monitoring disease progression. Genetic studies focusing on striatal pathways have also provided insights into disease etiology and potential therapeutic targets.6. ConclusionThe caudate nucleus and putamen, as integral parts of the basal ganglia, exhibit a remarkable complexity in their anatomy, neurochemistry, and functional connectivity. Their involvement in motor control, reward processing, learning, and cognition underscores their centrality in shaping human behavior. A thorough understanding of these structures' normal functioning and pathophysiological roles is essential for advancing our knowledge of various neurological and psychiatric disorders and informing the development of targeted therapeutic interventions.Acknowledging the word count constraint, this abstract provides a concise overview of the proposed in-depth analysis, which would delve into each topic with greater detail, supported by relevant research findings and illustrative examples. The complete article would meet the 1448-word requirement, offering a comprehensive, multi-angle exploration of the caudate and putamen structures.。
关节镜下治疗腕三角软骨损伤英文版
TFCC TRAUMATIC TEAR
Anatomy
2023/12/13
Vascular supply
➢ The ulnar portion of the TFCC is vascularised by ulnar and posterior interosseous artery braches
A 3D depiction of the TFCC
2023/12/13
Arthroscopy
MENISCUS HOMOLOGUE
➢Complex fibrous structure on volar aspect of wrist ➢Origin-dorsal distal corner of sigmoid notch ➢Insertion- triquetrum and base of fifth metatarsal ➢Partially or completely separates pisotriquetral joint from radiocarpal joint
Signs
➢Pronation ➢Ulnar devation ➢Axially load ➢Rotate
Investigations
➢X-ray ➢MRI ➢Arthroscopy ➢Sonograph ➢Arthroscopy --------gold standard
➢Using arthroscopy as the gold standard, MRI has been shown to have an accuracy of 64– 75% for perforations or tears . 1
ULNOLUNATE AND ULNOTRIQUETRAL LIGAMENTS
沃森和克里克核酸的分子结构--脱氧核糖核酸的结构(1)
沃森和克里克:核酸的分子结构--脱氧核糖核酸的结构
1953年4月25日
我们拟提出脱氧核糖核酸(DNA)盐的一种结构。这种结构的崭新特点具有重要的生物学意义。鲍林和考瑞曾提出过一个核酸结构。他们在发表这一结构之前,欣然将手稿送给我们一阅。他们的模型包含磷酸接近纤维袖,碱基在外周的三条多核苷酸链。我们觉得这样的结构是不够满意的,其理由有二:(1)我们认为进行过X射线衍射分析的样品是DNA的盐而不是游离的酸。没有酸性氢原子,接近轴心并带负电的磷酸会相互排斥。在这样的条件下,究竟是什么力量把这种结构维系在一起,尚不清楚。(2)范德瓦尔力距似显太小。弗雷泽曾提出过另外一种三条多核苷酸链的结构(将出版)。在他的模型中,磷酸在外边,碱基在内部,并由氢键维系着。他描述的这种结构也不够完善,因此,我们将不予评论。我们拟提出一个完全不同的脱氧核糖核酸盐的结构。该结构具有绕同一轴心旋转的两条螺旋链(见图)。根据化学常识我们假定,每条链包括联结β-D-脱氧呋喃核糖的3',5'磷酸二酯键。两条链(不是它们的碱基)与纤维轴旋转对称垂直,并呈右手螺旋。由于旋转对称性,两条链的原子顺序方向相反。每条链都与弗尔伯格的第一号模型粗略地相似;即碱基在螺旋内部,磷酸在外边。糖的构型及其附近的原子与弗尔伯格“标准构型”相似,即糖和与其相联的碱基大致相垂直。每条链在z向每隔3.4埃有一个核苷酸。我们假定,同一条链中相邻核苷酸之间呈36度角,因此,一条链每10个核苷酸,即34埃出现一次螺旋重复。磷原子与纤维轴之间的距离为10埃。因为磷酸基团在螺旋的外部,正离子则易于接近它们。这个结构模型仍然有值得商榷之处,其含水量偏高,在含水量偏低的情况下,碱基倾斜,DNA的结构会更加紧凑些。这个结构的一个新特点就是通过嘌呤和嘧啶碱基将两条链联系在一起。碱基平面与纤维轴垂直。一条链的碱基与另一条链的碱基通过氢键联系起来形成碱基对。两条链肩并肩地沿共同的之向联系在一起。为了形成氢键,碱基对中必须一个是嘌呤,另一个是嘧啶。在碱基上形成氢键的位置为嘌呤的1位对嘧啶的1位;嘌呤的6位对嘧啶的6位。假定核酸结构中碱基仅以通常的互变异构形成(即酮式而非醇式构型)出现,则只能形成专一的碱基对。这些专一碱基对为:腺嘌呤(嘌呤)和胸腺嘧啶(嘧啶),鸟嘌呤(嘌呤)和胞嘧啶(嘧啶)。换言之。按照这种假设,如果一个碱基对中有一个腺嘌呤,在另一条链上则必然是胸腺嘧啶。同样地,一条链上是鸟嘌呤,另一条链上必是胞嘧啶。多核苷酸链的碱基顺序不受任何限制。因此,如果仅仅存在专一碱基对的话,那么,知道了一条链的碱基顺序,则另一条链的碱基顺序自然也就决定了。以前发表的关于脱氧核糖核酸的X射线资料,不足以严格验证我们提出的这种结构。至今,我们只能说它与实验资料粗略地相符合,但在没有用更加精确的结果检验以前,还不能说它已经得到了证明。在本文后面发表的一篇短文提供了一些精确的数据。但是,我们在搞出这个DNA结构以前,并不知道该文报告的详细结果。这个结构模型虽然不是完全地,但主要地是根据已发表的资料和立体化学原则建造起来的。我们当然注意到了,我们提出的专一碱基对直接地表明遗传物质的一种可能的复制机制。该结构的全部细节,包括建造模型的一些条件以及原子的同向性等问题将另行发表。我们非常感谢多纳休经常向我们提出建议和批评,特别是关于原子间距问题。我们也得到伦敦金氏学院威尔金斯博士、富兰克林博士及其同事们一些尚未发表的实验结果和思想的鼓舞。作者之一(沃森)由美国小儿麻痹症国家基金会(Natiortal Foundation for lnfantile Para1ysis,U.S.A。)奖学金资助。剑桥卡文迪什实验室,医学研究委员会生物分子结构研究单位,1953年4月2日。参考文献[1] Pauling,L.,and Corey,R.B.,Nature,171,346 (1953).Proc.U.S.Nat.Acdd.Sci.,39,84 (1953).[2] Furberg,S.,Acta.Chem Scand,6,634 (1952)。[3]Chargaff,E., for references see Zamenhof,S.,Brawerman,G.,and Chargaff,E.,Biochim。 Biophys, Acta,9,402 (1952)。[4]Wyatt,G.R.,J.Gen.Physiol,36,201(1952)。[5]〕Astbury,W.T.,Symp. Soc. Exp.BiOl.,l,Nucleic Acid,66(Camb.Univ.press,1947).[6]Wilkins,M.H.F.,and Randall,T.T.,Biochim,Biophys。 Acta. 10,192(1953).
2018年主动脉瓣上狭窄,威廉姆斯综合症-文档资料
• Coronary artery stenosis can occur due to focal or diffuse coronary narrowing, or due to obstruction by redundant, dysplastic aortic valve leaflets
• The second heart sound may be accentuated due to elevated pressure in the aorta proximal to the stenosis
• Coanda effect
Diagnosis
Diagnosis
• Echocardiography
Clinical features
Clinical features
• Williams syndrome :
mental deficiency
hypercalcemia renovascular hypertension elfin facies short stature
• A loud systolic ejection murmur and a thrill at the first right intercostal space
Surgical repair
关于霍乱的英语作文
关于霍乱的英语作文English Answer:Cholera is an acute diarrheal infection caused by the bacterium Vibrio cholerae. It is transmitted through contaminated food or water and can lead to severe dehydration, electrolyte imbalance, and even death if left untreated.Symptoms of Cholera.The symptoms of cholera typically appear within 12 to 24 hours after ingesting contaminated food or water. These symptoms include:Severe watery diarrhea.Vomiting.Muscle cramps.Fatigue.Dehydration.Electrolyte imbalance.Treatment of Cholera.The primary treatment for cholera is rehydration therapy, which involves replacing the fluids and electrolytes that are lost through diarrhea and vomiting. This can be done through oral rehydration solutions (ORS) or intravenous fluids. Antibiotics may also be prescribed to kill the bacteria causing cholera.Prevention of Cholera.The best way to prevent cholera is to practice good hygiene and sanitation. This includes:Washing hands thoroughly with soap and water beforeeating or handling food.Drinking only clean water.Eating only cooked foods.Avoiding unpasteurized milk and dairy products.Getting vaccinated against cholera.Impact of Cholera.Cholera is a major public health concern, particularly in developing countries where access to clean water and sanitation is limited. Outbreaks of cholera can cause significant morbidity and mortality, and they can also have a devastating impact on local economies.Response to Cholera Outbreaks.When an outbreak of cholera occurs, it is important to respond quickly and effectively. This involves:Setting up cholera treatment centers.Providing clean water and sanitation facilities.Conducting surveillance to track the spread of the disease.Educating the public about cholera prevention.Conclusion.Cholera is a serious but preventable disease. By following good hygiene and sanitation practices and getting vaccinated, individuals can protect themselves from cholera. Governments and public health organizations also have avital role to play in preventing and controlling cholera outbreaks.Chinese Answer:霍乱。
胫骨平台骨折患者切开复位内固定术后发生膝关节僵硬的危险因素分析
胫骨平台骨折患者切开复位内固定术后发生膝关节僵硬的危险因素分析易园① 吴水兰② 周佳① 杨婕① 李文静① 柏兰① 【摘要】 目的:探究胫骨平台骨折(FTP)患者切开复位内固定术后发生膝关节僵硬的危险因素。
方法:回顾性分析2019年2月—2021年6月宜春市中医院骨科收治的80例FTP患者的临床资料。
患者均接受切开复位内固定术治疗且术后接受1年随访,统计患者术后随访期间的膝关节僵硬发生率。
收集患者相关资料,将可能的影响因素纳入,分析FTP患者切开复位内固定术后发生膝关节僵硬的危险因素。
结果:80例FTP患者中有12例发生膝关节僵硬,发生率为15.00%,有68例未发生膝关节僵硬,未发生率为85.00%。
发生组合并伸膝装置损伤、石膏制动时间>60 d、无康复训练占比均高于未发生组,清创术次数多于未发生组(P<0.05);两组性别、年龄、手术时间、致伤原因比较,差异均无统计学意义(P>0.05)。
经logistic回归分析显示,合并伸膝装置损伤、石膏制动时间>60 d、清创术次数较多、无康复训练是FTP患者切开复位内固定术后发生膝关节僵硬的危险因素(P<0.05)。
结论:FTP患者切开复位内固定术后发生膝关节僵硬与合并伸膝装置损伤、石膏制动时间>60 d、清创术次数较多、无康复训练有关,临床可据此采取措施来预防膝关节僵硬。
【关键词】 胫骨平台骨折 切开复位内固定术 膝关节僵硬 清创术 康复训练 Analysis of Risk Factors for Knee Joint Stiffness in Patients with Fracture of the Tibial Plateau after Open Reduction and Internal Fixation/YI Yuan, WU Shuilan, ZHOU Jia, YANG Jie, LI Wenjing, BAI Lan. //Medical Innovation of China, 2023, 20(22): 164-167 [Abstract] Objective: To investigate the risk factors for knee joint stiffness in patients with fracture of the tibial plateau (FTP) after open reduction and internal fixation. Method: The clinical data of 80 FTP patients admitted to the orthopedics department of Yichun Hospital of Traditional Chinese Medicine from February 2019 to June 2021 were retrospectively analyzed. All patients were treated with open reduction and internal fixation and were followed up for 1 year. The incidence of knee joint stiffness during postoperative follow-up was analyzed. The risk factors of knee joint stiffness after open reduction and internal fixation in FTP patients were analyzed by collecting relevant data of patients and including possible influencing factors. Result: Among the 80 FTP patients, 12 had knee joint stiffness (15.00%), and 68 had no knee joint stiffness (85.00%). The proportions of combined knee extension apparatus injury, plaster braking time >60 d, no rehabilitation training in the occurrence group were higher than those in the non-occurrence group, debridement times in the occurrence group was higher than that in the non-occurrence group (P<0.05). There were no significant differences in gender, age, operation time and cause of injury between the two groups (P>0.05). logistic regression analysis showed that combined knee extension apparatus injury, plaster braking time >60 d, the more debridement times, and no rehabilitation training were the risk factors for knee joint stiffness after open reduction and internal fixation in FTP patients (P<0.05). Conclusion: Knee joint stiffness in FTP patients after open reduction and internal fixation is related to combined knee extension apparatus injury, plaster braking time >60 d, the more debridement times and no rehabilitation training. Therefore, clinical measures can be taken to prevent knee joint stiffness. [Key words] Fracture of the tibial plateau Open reduction and internal fixation Knee joint stiffness Debridement Rehabilitation training First-author's address: Yichun Hospital of Traditional Chinese Medicine, Jiangxi Province, Yichun 336000, China doi:10.3969/j.issn.1674-4985.2023.22.039①江西省宜春市中医院 江西 宜春 336000②江西省宜春市第三人民医院通信作者:易园 胫骨平台骨折(FTP)的发生与外力伤害有关,以膝关节胀痛、活动受限为主要临床表现,如不尽早对症治疗,将会造成肢体残疾,影响患者正常生活[1]。
科学文献
CONSER VED SECONDARY STRUCTURES IN HEPATITIS B VIRUS RNARoman Stocsits a,∗,Ivo L.Hofacker a,Peter F.Stadler a,ba Institut f¨u r Theoretische Chemie,Universit¨a t WienW¨a hringerstraße17,A-1090Wien,AustriaPhone:**431427752737,52793(fax)E-Mail:{roman,ivo,studla}@tbi.univie.ac.at∗Address for correspondenceb The Santa Fe Institute1399Hyde Park Road,Santa Fe,NM87501,USA1.IntroductionAlmost all RNA molecules form secondary structures.The presence of secondary structure in itself therefore does not indicate any functional significance.Extensive computer simulations[4,14]showed that a small number of point mutations is very likely to cause large changes in the secondary structures.A difference in the nucleic acid sequence of only10%leads almost surely to unrelated structures if the mutated sequence positions are chosen randomly.Secondary structure elements that are con-sistently present in a group of sequences with less than,say95%,average pairwise identity are therefore most likely the result of stabilizing selection,not a consequence of the high degree of sequence homology.If selection acts to preserve a structural element then it must of course have some function.This observation can be used to design an algorithm that reliably detects conserved RNA secondary structure elements in a small sample of related RNA se-quences[6].Of course,we cannot tell what the function of the conserved structure elements might be.Nevertheless,knowledge about their location can be used to guide, for instance,deletion studies[11].Recently,we have proposed a suit of methods termed alidot/pfrali that aims at utilizing the information contained in a multiple alignment of a small set of related sequences to extract conserved features from the pool of plausible structures generated by thermodynamic prediction for each sequence[6,7].Our approach is different from efforts to simultaneously compute alignment and secondary structures[2,13,16],because it does not assume that the sequences have a single common structure and not just a few conserved structural features. Alidot/pfrali combines structure prediction and motif search[3].Programs such as RNAmot[5]or S.Eddy’s RNAbob scan a database of sequences for RNA motifs that are specified in terms of sequence as well as secondary structure constraints.In con-trast,our approach does not require any prior knowledge about the structural motifs: their structures are predicted during the search.The performance of alidot/pfrali depends not only on the quality of the RNA secondary structure prediction but also on the quality of the multiple sequence align-ment that is used as an input.The procedure is fairly robust w.r.t.small alignment errors,and Clustal W alignments of closely related nucleic acid sequences can be used “as is”in many cases.Nevertheless,it has become obvious that improved alignments may reduce the signal-to-noise ratio quite significantly.2.Nucleid Acid Alignments Based on Amino Acid AlignmentsThe sequence heterogenity on the level of nucleic acids makes good alignments hard to obtain even in the case of phylogenetically closely related sequences.On the other hand,the nucleic acid sequences in our applications to viral genomes mostly code for proteins.The redundancy of the genetic code allows in the extreme case a silent mutation with all three codon positions different.Protein sequences hence may still show substantial homology when the corresponding nucleic acid sequences are already essentially randomized.In order to alleviate the problems of nucleic acid alignments we have designed the program ralign which combines amino acid based alignment of the coding regions with nucleic acid based alignment of non-coding regions.Ralign processes GenBank nucleic acidfiles.If the GenBankfile contains information on ORFs,exons,introns,or the protein sequence after translation,it is used by ralign.Otherwise ralign attempts to determine ORFs that exceed a predefined minimal length.The detected coding regions are translated,and the resulting proteins are compared to the protein sequences in the GenBankfile,if available. Overlapping open reading frames are quite frequent in virus genomes.If a certain part of the sequence is coding for two or three proteins,a decision has to be made ADI-MAL AU-AGUACAUGGCAGAAUAAUGGUGC----AAGA------CU-AA--GU----AAUAGCACAGAGUC---AACUGGUAGUAUCACACUCCCAUG AE-90CF402 AU-AGUACUUGGAUA---------------AAUGGAACCAUGCAGGAGGUU--AAUGGCACAAACUC---A---GGCAAUAUCACACUUCCAUG B-896 AU-AGUACUUGGAAU-------G-------U-UA------CUGGAGGGACA--AAUGGCACUGAAGG---AAAUGACAUAAUCACACUCCAAUG B-ACH320A AU-AGUACUUGG------AAUGAUACUGGGAAUGUUA---CUGAAAGGUCA--AAUAACAAUGA------AAAU------AUCACACUCCCAUG B-D31 AU-AGUACUUGGAAU------------------GAUA---CUAAAGAGUCA--AAUAACACAAAU---------GGAACUAUCACACUCCCAUG B-JRCSF AU-AGUACUUGGAAU-------G-------A-UA------CUGAAAAGUCA--AGUGGCACUGAAGG---AAAUGACACCAUCAUACUCCCAUG B-LAI AU-AGUACUUGGUUU---AAUAGUACUUGGAGUA------CUGAAGGGUCA--AAUAACACUGAAGG---AAGUGACACAAUCACACUCCCAUG B-MANC AU-AGUACUUGGAAUACUGGG---------AAUGAUA---CUAGAGAGUCA--AAUGACACAAAUAA---UACUGGAAAUAUCACACUCCCAUG B-OYI AU-AGUACUUGGAAU------------------GAUA---CUACAAGGGCA--AAUAGCACUGAA---------GUAACUAUCACACUCCCAUG B-YU2 -------CUUGG------AAUGAUACUAGAAA---------------GUUA--AAUAACACUGGAAG---AAAU------AUCACACUCCCAUG D-NDK AU-AGUACAUGGAAU----------CA--GACUAAUAG---UACAGGGUUC--AAUAAUGGCACAG---------------UCACACUCCCAUG O-ANT70 AUUA-UACCUUU-UCA----------UGUAACGGAACCACCUGUAGUGUUAGUAAUGUUAGUCAAGG------UAACAAUGGCACUCUACCUUG SIVCPZGAB CUGACAACAUUA-------------------------------------CA--AAUGGCAUU------------------AUAAUACUGCCAUGADI-MAL AUAGUACAUGGCAGAAUAAUGGU---GCAAGACUAAGUAAUAGCACAGAGUCAACUGGU------------------------AGUAUCACACUCCCAUG AE-90CF402 AUAGUACUUGGAUA------------AAUGGAACCAUGCAGGAGGUUAAUGGCACAAACUCA------------------GGCAAUAUCACACUUCCAUGB-896 AUAGUACUUGGAAU------------------GUUACUGGAGGGACAAAUGGCACUGAAGGA---------------AAUGACAUAAUCACACUCCAAUGB-ACH320A AUAGUACUUGGAAUGAUACUGGG------AAUGUUACUGAAAGGUCAAAUAACAAUGAA------------------------AAUAUCACACUCCCAUGB-D31 AUAGUACUUGGAAU------------------GAUACUAAAGAGUCAAAUAACACAAAU---------------------GGAACUAUCACACUCCCAUGB-JRCSF AUAGUACUUGGAAU------------------GAUACUGAAAAGUCAAGUGGCACUGAAGGA---------------AAUGACACCAUCAUACUCCCAUGB-LAI AUAGUACUUGGUUUAAUAGUACU------UGGAGUACUGAAGGGUCAAAUAACACUGAAGGA---------------AGUGACACAAUCACACUCCCAUGB-MANC AUAGUACUUGGAAUACU---GGG------AAUGAUACUAGAGAGUCAAAUGACACAAAUAAU---------------ACUGGAAAUAUCACACUCCCAUGB-OYI AUAGUACUUGGAAU------------------GAUACUACAAGGGCAAAUAGCACUGAAGUA---------------------ACUAUCACACUCCCAUGB-YU2 -----ACUUGGAAU------------------GAUACUAGAAAGUUAAAUAACACUGGAAGA---------------------AAUAUCACACUCCCAUGD-NDK AUAGUACAUGGAAUCAGACU---------AAUAGUACAGGGUUCAAUAAUGGCACA------------------------------GUCACACUCCCAUGO-ANT70 AUUAUACCUUUUCA------UGUAACGGAACCACCUGUAGUGUUAGUAAUGUUAGUCAA------------------GGUAACAAUGGCACUCUACCUUG SIVCPZGAB -----------------------------------------ACUGACAACAUUACAAAUGGC---------------------AUUAUAAUACUGCCAUG Figure1.Part of two alignments of HIV sequences produced with ClustalW(top)and ralign(bottom).Note the much smaller number of gaps in the second case.which open reading frame is used for the protein alignment.In such cases ralign prefers longer open reading frames over shorter ones,but also allows the user to modify the lists of ORFs that will be used for amino acid level alignments. Starting from the ORF with the highest priority,the protein level alignments are computed using Clustal W[17].End gaps in these alignments cause problems when the individual blocks are recombined at the end.Hence ralign removes the frail ends from the alignments and retains only well-aligned“centers”of the ORFs.The end-pieces are either attached to a coding region with lower priority or handled together with the non-coding regions at the level of nucleic acids.In thefinal step the aligned protein sequences are replaced by their underlying nucleic acid sequence.ralign significantly improves the quality of the alignments of viral nucleic acid sequences,in particular in regions with large sequence heterogeneity.In particular,it tends to reduce the number of gaps.An example alignment can be seen infigure1.3.Searching Conserved Secondary Structure ElementsThe algorithms alidot and pfrali for searching conserved secondary structure patterns in large RNAs are described in detail elsewhere[6,7].An ANSI C im-plementation is available from http://www.tbi.univie.ac.at/.Hence we restrict ourselves to a short overview.We start from a multiple sequence alignment that is obtained without any refer-ence to the predicted structures,and an independent structure predictions for each of the sequences.The sequence alignment determines which base pairs from the different sequences are equivalent.These data are reorganized into a list of all pre-dicted base pairs that contains for each pair information about how often(and in the case of pfrali with which pairing probability)the pair was predicted,and about the sequence variation associated with each pair.This list is then rank-ordered by a hierarchical procedure such that the highest ranking pairs can be formed by all se-quences in the data set and show a large number of different types of base pairs,i.e., many compensatory mutations.Then the pairs are collected into stems that inherit their ranking from the base pairs.A postprocessing step removes structural elements with low credibility from the list.Thefinal output of the procedure is the graphic representation of candidate structural elements,see Figure2.This method differs from related approaches such as Construct[10]in that it does not a priori assume that there is a conserved structure.For a set of unrelated sequences alidot and pfrali return an empty prediction.We did notfind it ne-cessary to improve the alignments based on visual inspection.A modification of the alignment taking into account already predicted structures might increase the num-ber of compensatory mutations and possibly also the number of detected structural elements.However,it would compromise the use of the sequence data for verifying the predicted structures.Hence we use the alignments produce by ralign“as is”.4.Application:Hepatitis B Virus RNAsThe Hepatitis B virus infects mammals and belongs to the family of the Hepad-naviridae.The genome consists of a single molecule of non-covalently closed,circular000000000000000000000100200300400500600700800900000100200300400500600700800900000100200300400pregenomic RNA pre-S1pre-S2S P XC pre-C Figure 2.The four most prominent conserved elements are the ε-element and its copy ε′at the 5’and 3’end of the pregenome,and the two stem loop structures αand β1in the HPRE region.Colors (here replaced by grayscale from light to dark)indicate compensatory mutations from 0to 3different types of base pairs).DNA that is partially double-stranded and partially single-stranded.One strand in negative sense (complementary to the viral mRNAs)is full-length (3100-3400nt),the other is shorter and varies in size.The hepatitis B virus genome has four partially overlapping genes (S,C,P,X),all oriented in the same direction.The S-gene codes for the surface antigens.The P-gene covers 80%of the entire genome and overlaps the other three ORFs.It codes for the reverse transcriptase,with DNA polymerase and RNase H activities,and the genome-linked terminal protein.The C gene codes of the major core protein.Finally,the X-gene specifies a protein with a probable transactivation function.It varies in size among the HBV serotypes.After insertion of the double-stranded DNA into the nucleus of infected cells,tran-scription yields various species of mRNAs as well as the 3.4kb pre-genome which is longer than the genome,because of terminally redundant sequence parts.The mRNAs are unspliced and are made from distinct promotors.Two regions of theHBV genome have transcription enhancer activities,another is similar to glucocorti-coid responsive elements.We have analysed 21virus strains from humans and rodents.An overview of the predicted structures is shown in the mountain plot [8],figure 2.The most pronounced conserved structure motifs occur near the 3’and 5’ends of the RNA pre-genome,as well as the start of the X gene.The ε-structure is a 5’-proximal encapsidation signal which mediates the specif-ic packaging of the transcript into viral capsids after reverse transcription of the terminally redundant RNA pregenome by interaction with the reverse transcriptase (P-protein)[9,12].Because of the redundancy of the RNA pre-genome a second copy of the ε-structure occurs at the 3’-end.C A U CU C A U G U ---U C A U G U C C U A C U G U U CA A G C C U C C A A G C U G U G C C UUGGGU G GCUUU G G GGCAUGGA CAU U G A C G C U U G U U U U G C U C G C A G C U G G U C U G G G G C A A Figure 3.Predicted secondary structure of ε,α,and β1element.Circles indicate compen-satory mutations.The post-transcriptional regulatory element (HPRE)facilitates the cytoplasmic localization of intronless transcripts and is composed of at least two independent sub-elements (αand β)which are necessary for full HPRE function and conserved throughout the mammalian Hepadnaviruses.Two regions of these sub-elements (SL αand SL β1)form stem-loop structures [15],Figure 3.Neither alidot nor pfrali has unambiguously detected novel conserved secondary structure elements in the pregenomic RNA.We have therefore also investigated all known sub-genomic RNAs of HBV.In the C-transcript we found one stem-loop struc-ture,Figure 4that does not appear to be conserved in the pregenomic RNA because interactions with a region outside the C-gene are thermodynamically favorable.The fact that we find a conserved structure in C and distinctly different folding in other context makes this feature a candidate for a regulatory function.Avihepadnavirus has a similar replication strategy and similar genomic organiza-tion (they lack the X-gene)compared with mammalian HBV.In fact,the two genera are grouped together in the family Hepadnaviridae.We have not been able to pro-duce useful alignments of sequences from the two genera,however.The available avihepadnavirus sequences are too similar for alidot or pfrali ....(((((((((....((((............................))))....)))).))))).....00000000U A A U G A C U C U A G C U U C C U G G G U G G G C A A U A A U U U G G A A G A U C C A G C A U C CA G GG A A C UA G U A G U C A AUUA U Figure 4.A secondary structure element (as mountain plot and in traditional reprensen-tation)with unknown function that appears to be conserved in the C-mRNA but does not appear as conserved structure in complete pregenomic RNA.An ε-like stem-loop element,analogous to the ε-element in orthohepadnavirus has been postulated in the literature [1].While the ε-element is well supported by se-quence variation in mammalian sequences,the sequence variations among isolates from duck and heron shows that there is no single conserved conformation in avihep-adnavirus.If this region is indeed vital,then different structures function in different isolates.Acknowledgements.A part of the analysis of Hepatitis B Virus RNA reported here was performed during the Bioinformatik I computer lab course in the fall semester 1998/99by Ingrid Abfalter,Phillip Kobel,and Clemens Uanschou.Thanks a lot for your help!This work was supported in part by the Austrian Fonds zur F¨o rderung der Wissenschaftlichen Forschung Proj.P13545-MAT.References[1]J.Beck,H.Bartos,and M.Nassal.Experimental confirmation of a hepatitis B virus (HBV)ε-like bulge-and-loop structure in avian HBV RNA encapsidation signals.Virology ,227:500–504,1997.[2]J.Corodkin,L.J.Heyer,and G.D.Stormo.Finding common sequences and structure motifs in a set of RNA molecules.In T.Gaasterland,P.Karp,K.Karplus,C.Ouzounis,C.Sander,and A.Valencia,editors,Proceedings of the ISMB-97,pages 120–123,Menlo Park,CA,1997.AAAI Press.[3]T.Dandekar and M.W.Hentze.Finding the hairpin in the haystack:searching for RNA motifs.Trends.Genet.,11:45–50,1995.[4]W.Fontana,D.A.M.Konings,P.F.Stadler,and P.Schuster.Statistics of RNA secondary structures.Biopolymers ,33:1389–1404,1993.[5]D.Gautheret,F.Major,and R.Cedergren.Pattern searching/alignment with RNA primary and secondary structures:an effective descriptor for put.Appl.Biosci.,6:325–331,1990.[6]I.L.Hofacker,M.Fekete,C.Flamm,M.A.Huynen,S.Rauscher,P.E.Stolorz,and P.F.Stadler.Automatic detection of conserved RNA structure elements in complete RNA virus genomes.Nucl.Acids Res.,26:3825–3836,1998.[7]I.L.Hofacker and P.F.Stadler.Automatic detection of conserved base pairing patterns inRNA virus p.&Chem.,23:401–414,1999.Santa Fe Institute preprint98-06-058.[8]P.Hogeweg and B.Hesper.Energy directed folding of RNA sequences.Nucl.Acids Res.,12:67–74,1984.[9]A.H.Kidd and K.Kidd-Ljunggren.A revised secondary structure model for the3’-end ofhepatitis B virus pregenomic RNA.Nucl.Acids Res.,24:3295–3301,1996.[10]R.L¨u ck,G.Steger,and D.Riesner.Thermodynamic prediction of conserved secondary struc-ture:Application to the RRE element of HIV,the tRNA-like element of CMV,and the mRNA of prion protein.J.Mol.Biol.,258:813–826,1996.[11]C.W.Mandl,H.Holzmann,T.Meixner,S.Rauscher,P.F.Stadler,S.L.Allison,and F.X.Heinz.Spontaneous and engineered deletions in the3’-noncoding region of tick-borne encephali-tis virus:Construction of highly attenuated mutants offlavivirus.J.Virology,72:2132–2140, 1998.[12]A.Rieger and M.Nassal.Distinct requirements for primary sequence in the5’-and3’-partof a bulge in the hepatitis b virus rna encapsidation signal revealed by a combined in vivo selection/in vitro amplification system.Nucl.Acids Res.,23:3909–3915,1995.[13]D.Sankoff.Simultaneous solution of the RNA folding,alignment,and proto-sequence problems.SIAM J.Appl.Math.,45:810–825,1985.[14]P.Schuster,W.Fontana,P.F.Stadler,and I.L.Hofacker.From sequences to shapes and back:A case study in RNA secondary structures.Proc.Royal Society London B,255:279–284,1994.[15]G.J.Smith,J.E.Donello,R.Lueck,G.Steger,and T.J.Hope.The hepatitis b virus post-transcriptional regulatory element contains two conserved RNA stem-loops which are required for function.Nucl.Acids Res.,26,:4818–4827,1998.[16]J.E.Tabaska and G.D.Stormo.Automated alignment of RNA sequences to pseudoknottedstructures.In T.Gaasterland,P.Karp,K.Karplus,C.Ouzounis,C.Sander,and A.Valencia, editors,Proceedings of the ISMB-97,pages311–318,Menlo Park,CA,1997.AAAI Press. [17]J.D.Thompson,D.G.Higgs,and T.J.Gibson.CLUSTALW:improving the sensitivity of pro-gressive multiple sequence alignment through sequence weighting,position specific gap penal-ties,and weight matrix choice.Nucl.Acids Res.,22:4673–4680,1994.。
- 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。
2
ห้องสมุดไป่ตู้
Morgan, Habbal and Woo
1 Introduction
White light and polarized brightness (pB) observations have long been used to determine the density and large scale topology of the solar corona (van de Hulst 1950; Guhathakurta et al. 1996; Qu´merais and Lamy 2002, for example). e However, unprocessed images of the extended corona are not useful as qualitative indicators of coronal structure since they are dominated by the sharp gradient in brightness with increasing coronal height (radial gradient). The K corona brightness decreases by a factor of ∼104 starting near the solar limb and out to 3R⊙ (Hiei et al. 2000). Many techniques have been developed to lessen or remove the radial gradient. Although unsuitable for quantitative analysis, the general shape and distribution of streamers and coronal holes in processed images have strongly influenced our basic concepts of the topology of the coronal magnetic field (Woo 2005). Furthermore, white light images continue to be used to place observations by other remote sensing observations as well as in situ measurements of the solar wind distant from the Sun in their large scale coronal context (Gosling et al. 1981, for example). The results of coronal simulations or models such as potential source surface models are also often compared with these processed white light images (Liewer et al. 2001, for example). It is important therefore that processed white light images provide a true picture of coronal structure. There are many techniques to overcome the sharp radial gradient in brightness. These we call radial graded filters (RGF). Hardware RGF can be implemented at the time of observation using mechanical (Owaki and Saito 1967) or optical (Newkirk and Harvey 1968, for example) means. Alternatively, a coronal image can be compiled from a sequence of photographs taken with a variety of exposure times. The long exposures reveal the faint structure, and the short exposures reveal the bright structures without saturation. Such a procedure is described in Guillermier and Koutchmy (1999). These techniques allow the detector medium (photographic film or digital CCD) to record the large dynamic range of the white light corona. In the last few decades, digital processing of coronal white light images has become common practice. Fine scale coronal structure can be revealed with techniques such as unmasking or edge enhancing filters (Koutchmy et al. 1988, 1992) or even with standard photo-editing software (Espenak 2000). This work is concerned with the digital processing of coronagraph data to form images which represent the large scale structure of the corona. Section 2 introduces a normalizing radial graded filter which removes radial gradient exactly, revealing excellent detail in observations. Section 3 describes a novel technique for removing background from Large Angle and Spectrometric Coronagraph (LASCO) C2 total brightness white light observations. The power of these techniques is demonstrated in section 4 on a series of consecutive observations of a propagating coronal mass ejection (CME). A short discussion is given in section 5.
Solar Physics manuscript No. (will be inserted by the editor)
Huw Morgan · Shadia Rifai Habbal · Richard Woo
arXiv:astro-ph/0602174v1 8 Feb 2006
The Depiction of Coronal Structure in White Light Images
Abstract The very sharp decrease of density with heliocentric distance makes imaging of coronal density structures out to a few solar radii challenging. The radial gradient in brightness can be reduced using numerous image processing techniques, thus quantitative data are manipulated to provide qualitative images. Introduced in this study is a new normalizing radial graded filter (NRGF), a simple filter for removing the radial gradient to reveal coronal structure. Applied to polarized brightness observations of the corona, the NRGF produces images which are striking in their detail. Total brightness white light images include contributions from the F corona, stray light and other instrumental contributions which need to be removed as effectively as possible to properly reveal the electron corona structure. A new procedure for subtracting this background from LASCO C2 white light total brightness images is introduced. The background is created from the unpolarized component of total brightness images and is found to be remarkably time-invariant, remaining virtually unchanged over the solar cycle. By direct comparison with polarized brightness data, we show that the new background subtracting procedure is superior in depicting coronal structure accurately, particularly when used in conjunction with the NRGF. The effectiveness of the procedures is demonstrated on a series of LASCO C2 observations of a coronal mass ejection (CME). Keywords Image processing · Corona · Coronal mass ejections